www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion Innovations investee Myconostica secures Canadian license for diagnostic product
Amphion Innovations’ (AIM: AMP) 22 percent owned medical diagnostic company Myconostica has received a license from Health Canada for the sale of its diagnostic test MycAssay Aspergillus, paving the way for its introduction into the Canadian healthcare market.
MycAssay Aspergillus is used for the detection of Aspergillus DNA in lower respiratory tract samples, aiding physicians to make a diagnosis in immunocompromised patients suspected of having an infection caused by Aspergillus spp to enable appropriate drug treatment to be administered to improve patient outcomes.
The company has already signed an agreement with Inverness Medical Canada Inc, a subsidiary of Inverness Medical Innovations (NYSE: IMA), to act as the exclusive distributor of its products in Canada.
“There is a growing awareness of the risk of patients getting life threatening fungal disease and we are delighted that, with our new partners in Canada, Inverness Medical, we can start to introduce our products into Canadian healthcare. We are actively working to licence all our products to this key market,” said chief business officer of Myconostica, John Thornback.
Amphion’s fully-diluted ownership stake in Myconostica was 22.14 percent as of 30 June 2009, valued at US$2.3 million.
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
Amphion’s investments also include 38.5 percent in Motif Biosciences, a 19.99 percent stake in Kromek, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp 25 percent in Private Markets and 14.6 percent in WellGen Inc.
It fully controls DataTern, which was established in order to commercialise selected intellectual property opportunities in partnership with Amphion's partner companies.
